On October 22, 2020 Alligator Bioscience reported that (Press release, Alligator Bioscience, OCT 22, 2020, View Source [SID1234568887])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Encouraging clinical safety data for ATOR-1017

The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented interim data that showed a good safety profile at clinically relevant dose levels. The dose evaluation will continue with yet higher doses and we expect to present safety and potentially efficacy data from the entire study in the spring of 2021. At the same time, we have shown strong Proof of Mechanism data for mitazalimab, while the ATOR-1015 program reported side effects at high dose levels.The nature of the reactions have lead to a need to re-design the planned clinical trial in malignant melanoma and to perform additional preclinical investigations. We will now focus our clinical investments to ATOR-1017 and mitazalimab. Both programs have first-in-class potential, and will move into clinical Phase II during 2021", commented CEO Per Norlén.

SIGNIFICANT EVENTS JULY – SEPTEMBER

Mitazalimab:

Positive biomarker data demonstrating Proof of Mechanism in clinical Phase I study performed by Janssen.
Clinical development program defined. The CTA for the upcoming Phase II study in pancreatic cancer is scheduled to be submitted in December 2020.
ATOR-1015:

Revised plan due to further evaluation of doses and adverse reactions, leading to delay of Phase Ib.
US composition of matter patent granted.
ATOR-1017:

Encouraging emerging safety data at clinically relevant dose levels in the ongoing Phase I study.
Preclinical:

Neo-X-Prime: New unique drug concept for tumorspecific treatment launched at 11th World Bispecific Summit.
Other:

Gayle Mills appointed Chief Business Officer.
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

Clinical focus on ATOR-1017 and mitazalimab:

Preparations to bring ATOR-1017 and mitazalimab to Phase II efficacy studies in 2021.
ATOR-1015: A partner will be sought for further clinical studies.
FINANCIAL SUMMARY

July-September 2020

Net sales, SEK 0.0 million (4.3).
Operating result, SEK -30.6 million (-58.5).
Result for the period, SEK -30.8 million (-56.6).
Earnings per share before and after dilution, SEK -0.43 (-0.79).
Cash flow for the period, SEK -32.7 million (-47.3).
Cash and cash equivalents, incl. interest-bearing securities, SEK 137.0 million (302.2)
January-September 2020

Net sales, SEK 4.4 million (4.4).
Operating result, SEK -110.2 million (-155.2).
Result for the period, SEK -108.8 million (-150.3).
Earnings per share before and after dilution, SEK-1.52 (-2.11).
Cash flow for the period, SEK 42.6 million (-27.8).
During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on cash flow.

Read the complete report in the pdf below.

Alligator will host a conference call today at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén will present and comment on the Q3 interim report and the focus of the clinical operations. The conference will be held in English. All necessary information to listen-in and ask questions are available on the following link: View Source